Ursula Anne Matulonis MD

Gynecologic Cancer

Chief, Division of Gynecologic Oncology, Brock-Wilson Family Chair, Dana-Farber Cancer Institute, Boston MA Professor of Medicine, Harvard Medical School, Boston MA

Join to View Full Profile

44 Binney St# DanaBoston, MA 02115
Phone+1 617-632-2334
Fax+1 617-632-3479

Summary

Dr. Ursula Matulonis is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital and Dana-Farber Cancer Institute. She received her medical degree from Albany Medical College and has been in practice 30 years. She specializes in the treatment of gynecologic cancers.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1990 - 1993
Presbyterian Medical Center of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1987 - 1990
Albany Medical CollegeClass of 1987

Certifications & Licensure

MA State Medical License 1990 - 2027
ME State Medical License 2022 - 2027
RI State Medical License 2022 - 2026
PA State Medical License 1990 - 1990
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2017
Boston Magazine Castle Connolly, 2008-2013
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 2
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 2
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod Start of enrollment: 2008 Aug 01
Active, not recruiting
Phase 2
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies Start of enrollment: 2009 Feb 01
Completed
Phase 2
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer Start of enrollment: 2009 Jun 01
Terminated
Phase 1, Phase 2
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer Start of enrollment: 2012 Aug 01
Withdrawn
Phase 2
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Start of enrollment: 2013 Jun 21
Completed
Phase 3
GSK1120212+GSK2141795 for Cervical Cancer Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Start of enrollment: 2016 Oct 01
Terminated
Phase 1
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
COMPLETED
PHASE3
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer Start of enrollment: 2022 Sep 28
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
Kelly J Fitzgerald, Panagiotis Konstantinopoulos, Ursula Matulonis, Joyce Liu, Neil Horowitz
Gynecologic Oncology. 2025-04-23
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo
Gynecologic Oncology. 2025-04-01
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, Carolyn Krasner, Susana M Campos
JCO Precision Oncology. 2025-04-01

Journal Articles

Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology
Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer Population
Khanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation

Lectures

Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and p...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. Engaging the Imm...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Niraparib for Ovarian Cancer. FDA Approvals and Their Incorporation into Clinical Practice
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Other

8 Takeaway Presentations from SGO 2018
Ursula Matulonis, MD, Op-Med
https://www.doximity.com/articles/e20ae63b-76d9-44fb-b629-fb90fbd9ef16
UpToDate, Wolters Kluwer Health - 2012-12-17

Authored Content

8 Takeaway Presentations from SGO 2018April 2018

Press Mentions

ImmunoGen ELAHERE Wins Accelerated FDA Approval for Ovarian CancerNovember 16th, 2022
Mirvetuximab Soravtansine-GynxNovember 15th, 2022
ImmunoGen Presents Full Results from Phase 3 SORAYA Trial of Mirvetuximab Soravtansine in Ovarian CancerMarch 21st, 2022
Join now to see all

Grant Support

Targeting Replication Stress and DNA Damage Response in Uterine CancerDANA-FARBER CANCER INST2024–2029
Targeting Replication Stress and DNA Damage Response in Uterine CancerDANA-FARBER CANCER INST2024–2029
Targeting Replication Stress and DNA Damage Response in Uterine CancerDANA-FARBER CANCER INST2024–2029
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grantDANA-FARBER CANCER INST2020–2025